|Bid||144.00 x 20000|
|Ask||145.00 x 20000|
|Day's Range||142.00 - 142.00|
|52 Week Range||79.50 - 144.00|
|Beta (5Y Monthly)||0.42|
|PE Ratio (TTM)||49.66|
|Forward Dividend & Yield||1.40 (0.99%)|
|Ex-Dividend Date||Nov 06, 2019|
|1y Target Est||N/A|
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating potential claims against certain officers and directors of ResMed, Inc. (NYSE: RMD) on behalf of long-term stockholders.
Shareholder rights law firm Robbins LLP is investigating whether certain officers and directors of ResMed Inc. (NYSE: RMD) breached their fiduciary duties to shareholders. ResMed develops, manufactures, and markets medical equipment for the treatment of sleep disordered breathing.
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
New CFO Deepak Ahuja is one of three new high-level hires at the South San Francisco-based subsidiary of Alphabet.
ResMed (NYSE: RMD) (ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2020 on Thursday, January 30, 2020, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this call.
ResMed (NYSE: RMD, ASX: RMD) today announced that Mick Farrell, chief executive officer, will present at the 38th Annual J.P. Morgan Annual Healthcare Conference on Monday, January 13, 2020, beginning at approximately 8:30 a.m. (Pacific Standard Time) at Westin St. Francis in San Francisco, CA.
Examining ResMed Inc.'s (NYSE:RMD) past track record of performance is a useful exercise for investors. It allows us...
At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we've gathered as a result gives us access to a wealth of collective knowledge based on these firms' portfolio holdings as of September 30. In this […]
Stocks traded near session highs as the S&P; 500 today climbed close to a record peak and Alphabet neared a buy point.
After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms' equity portfolios as of June 28. The results of that effort will be put on display in this article, as […]
With more than 10 million cloud-connected CPAP and other breathing devices on the market, CEO Mick Farrell completely understands why patients are wary about letting those devices send data to the cloud.
President and COO ResMed Inc. of Resmed Inc (30-Year Financial, Insider Trades) Robert Andrew Douglas (insider trades) sold 4,111 shares of RMD on 07/15/2019 at an average price of $124.5 a share. Continue reading...
CEO of Resmed Inc (NYSE:RMD) Michael J. Farrell sold 6,651 shares of RMD on 07/08/2019 at an average price of $123.76 a share.
During Friday night's Lightning Round of Mad Money, Jim Cramer said this about ResMed Inc. In the daily bar chart of RMD, below, we can see a wide-swinging sideways market for this stock. The daily On-Balance-Volume (OBV) line has been steady from March, and is close to making a new high for the move up.
ResMed gapped up out of a downward-sloping flat base, surging on earnings. The maker of sleep apnea products reported better-than-expected earnings growth and the third straight quarter of slowly accelerating revenue growth.
Mick Farrell, ResMed CEO, joined Yahoo Finance from the New York Stock Exchange as the company celebrates its 20th year as a publicly traded company.